Neuromuscular

The phase 4 study will enroll 300 patients with amyotrophic lateral sclerosis who have started treatment with edaravone (Radicava; Mitsubishi Tanabe Pharma America).

Argenx’s antibody fragment to target the neonatal Fc receptor is the first in its class, with its approval backed by data from the phase 3 ADAPT trial.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 17, 2021.

Clinicians have begun to incorporate more holistic ways to approach the treatment of multiple sclerosis symptoms by focusing on better overall health, exercising, and dieting.

Ellie Harrington, lecturer in genetic counseling, provides answers for patients with ALS who might be unfamiliar with genetic testing and counseling.

The CEO of ZZ Biotech outlined the design of the phase 2 trial of 3KA-APC, which will enroll 16 patients with amyotrophic lateral sclerosis. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

Statistical significance was observed for both the MycarinG study’s primary and secondary end points in a population of 200 patients with myasthenia gravis treated with the UCB agent.

Kent Pryor, PhD, the CEO of ZZ Biotech, provided insight into a phase 2 trial that will evaluate the safety and efficacy of the investigational treatment in 16 patients with amyotrophic lateral sclerosis.

The cohort study was conducted using data from the Danish Multiple Sclerosis Registry for women with clinically isolated syndrome and relapsing remitting multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 10, 2021.

Despite displaying safety, after accounting for baseline differences between groups, statistically significant clinical improvement was not observed in key secondary outcomes, exploratory clinical outcomes, or responder analyses.

The FDA has previously granted the Acadia Pharmaceuticals treatment fast track status and orphan drug designation for Rett syndrome.

Prespecified and post hoc analyses explored the heterogeneity of disease at baseline, with meaningful treatment effect indicated in a subset of patients with less severe ALS.

Here's what is coming soon to NeurologyLive®.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

The investigational ZZ Biotech treatment was previously evaluated in patients with acute ischemic stroke, with exploratory analyses showing a trend towards lower hemorrhage rate.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 3, 2021.

After previously showing proof-of-concept in a phase 2 setting, investigators will continue to evaluate efficacy and safety of apitegromab, potentially the first muscle-directed therapy for patients with SMA.

Expert clinicians offer their perspectives on transitional care in pediatric MS, a biomarker for SUDEP, and a novel approach to narcolepsy, among other topics.

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 26, 2021.